The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AMRYT PHARMA PLC | SPONSORED ADS | 03217L106 | 15,322,649 | 2,098,993 | SH | SOLE | 2,098,993 | 0 | 0 | ||
ARGENX SE | SPONSORED ADR | 04016X101 | 9,091,920 | 24,000 | SH | SOLE | 24,000 | 0 | 0 | ||
ARROWHEAD PHARMACEUTICALS IN | COM | 04280A100 | 44,758,568 | 1,103,515 | SH | SOLE | 1,103,515 | 0 | 0 | ||
ARVINAS INC | COM | 04335A105 | 23,055,522 | 673,941 | SH | SOLE | 673,941 | 0 | 0 | ||
BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 25,487,256 | 581,768 | SH | SOLE | 581,768 | 0 | 0 | ||
GENMAB A/S | SPONSORED ADS | 372303206 | 10,291,898 | 242,848 | SH | SOLE | 242,848 | 0 | 0 | ||
KYMERA THERAPEUTICS INC | COM | 501575104 | 15,710,099 | 629,411 | SH | SOLE | 629,411 | 0 | 0 | ||
MERUS N V | COM | N5749R100 | 22,154,726 | 1,432,109 | SH | SOLE | 1,432,109 | 0 | 0 | ||
PIERIS PHARMACEUTICALS INC | COM | 720795103 | 4,734,991 | 4,552,876 | SH | SOLE | 4,552,876 | 0 | 0 | ||
REGENXBIO INC | COM | 75901B107 | 20,359,473 | 897,684 | SH | SOLE | 897,684 | 0 | 0 | ||
SILENCE THERAPEUTICS PLC | ADS | 82686Q101 | 19,583,028 | 1,284,133 | SH | SOLE | 1,284,133 | 0 | 0 | ||
S&P BIOTECH ETF TR | UNIT | 78464A870 | 41,500,000 | 500,000 | SH | Put | SOLE | 0 | 0 | 500,000 | |
UNIQURE NV | SHS | N90064101 | 14,165,440 | 624,854 | SH | SOLE | 624,854 | 0 | 0 |